Re-purposing Drugs and Prominent Vaccines Efficacy against Covid-19: A Short Review

Authors: Prakash S, Rai SN, Dubey S and Singh MP*

Volume 6, Issue 1

Abstract

Coronavirus disease 2019 (COVID-19 or SARS-CoV-2) a newly outbreak of respiratory infection firstly reported in December 2019, in Wuhan, China has not only affected healthcare worldwide but also created global economic disruptions. As of now, more than 120 million cases have been reported with 2.6 million confirmed deaths so far as of mid-March 2021. With having high availability of transmission rate within the few months, it quickly speeded all across the globe. Although with the modern technologies in scientific research we are now in a better position to understanding and cope with this outbreak. Recently vaccine candidates like Pfizer/Biotech and Moderna received emergency approval from US FDA based on their clinical safety showed around 95 % efficacy profile in preventing infection. However, to vaccinate the majority of populations all around the globe in a limited time is extremely challenging especially in under developing countries. Here some of the repurposing drugs could be an alternative approach to reduce the mortality rate based on in vitro or in vivo studies. Additionally, numerous chemical drugs are also to be prescribed are underway based on the computational tools. In this mini-review, we have speculated some of the repurposing drugs against SARS-CoV-2 infection whether its effective or not, their life cycle mechanism, and some prominent vaccine efficacy.

Keywords: COVID-19; Re-Purposing Drugs; SARS-Cov-2; ACE2; Vaccine

View PDF